Clinical Trial: Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets

U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07868419) titled 'Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets' on Oct. 05.

Brief Summary: The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with IPF.

Study Start Date: Sept. 30

Study Type: INTERVENTIONAL

Condition: Idiopathic Pulmonary Fibrosis

Intervention: DRUG: NAL ER

Oral tablets

DRUG: Placebo

Oral tablets

Recruitment Status: RECRUITING

Sponsor: Trevi Therapeutics

Disclaimer: Curated by HT Syndication....